These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 27306885)

  • 21. Ramucirumab Clinical Development: an Emerging Role in Gastrointestinal Tumors.
    Sanchez-Gastaldo A; Gonzalez-Exposito R; Garcia-Carbonero R
    Target Oncol; 2016 Aug; 11(4):479-87. PubMed ID: 26887374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted inhibition of VEGF receptor 2: an update on ramucirumab.
    Clarke JM; Hurwitz HI
    Expert Opin Biol Ther; 2013 Aug; 13(8):1187-96. PubMed ID: 23803182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer.
    Diaz-Serrano A; Riesco-Martinez MC; Garcia-Carbonero R
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):585-95. PubMed ID: 27144874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economics of ramucirumab for metastatic colorectal cancer.
    Zeichner SB; Kohn CG; Goldstein DA
    Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):733-745. PubMed ID: 27828732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives.
    Calvetti L; Pilotto S; Carbognin L; Ferrara R; Caccese M; Tortora G; Bria E
    Expert Opin Biol Ther; 2015; 15(9):1359-70. PubMed ID: 26190526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A critical review on ramucirumab in the treatment of advanced urothelial cancer.
    Vlachostergios PJ; Lee A; Thomas C; Walsh R; Tagawa ST
    Future Oncol; 2018 May; 14(11):1049-1061. PubMed ID: 29231057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis.
    Roviello G; Pacifico C; Corona P; Generali D
    Invest New Drugs; 2017 Aug; 35(4):518-523. PubMed ID: 28285368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ramucirumab and its use in the treatment of hepatocellular carcinoma.
    Turkes F; Chau I
    Future Oncol; 2019 Mar; 15(9):979-988. PubMed ID: 30644314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ramucirumab for gastric cancer.
    Shitara K; Ohtsu A
    Expert Rev Gastroenterol Hepatol; 2015 Feb; 9(2):133-9. PubMed ID: 25431958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Somatic p.T771R KDR (VEGFR2) Mutation Arising in a Sporadic Angioma During Ramucirumab Therapy.
    Lim YH; Odell ID; Ko CJ; Choate KA
    JAMA Dermatol; 2015 Nov; 151(11):1240-3. PubMed ID: 26422291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence and risk of hypertension associated with ramucirumab in cancer patients: A systematic review and meta-analysis.
    Qi WX; Fu S; Zhang Q; Guo XM
    J Cancer Res Ther; 2016; 12(2):775-81. PubMed ID: 27461650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ramucirumab in the treatment of non-small cell lung cancer.
    Arrieta O; Zatarain-Barrón ZL; Cardona AF; Carmona A; Lopez-Mejia M
    Expert Opin Drug Saf; 2017 May; 16(5):637-644. PubMed ID: 28395526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
    Kurzrock R; Stewart DJ
    Clin Cancer Res; 2017 Mar; 23(5):1137-1148. PubMed ID: 27940520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer.
    Losanno T; Rossi A; Maione P; Napolitano A; Gridelli C
    Expert Opin Biol Ther; 2016 Jun; 16(6):747-58. PubMed ID: 26950292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase ib study of safety and pharmacokinetics of ramucirumab in combination with paclitaxel in patients with advanced gastric adenocarcinomas.
    Ueda S; Satoh T; Gotoh M; Gao L; Doi T
    Oncologist; 2015 May; 20(5):493-4. PubMed ID: 25888272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ramucirumab for metastatic gastric or gastroesophageal junction cancer: results and implications of the REGARD trial.
    Liguigli W; Tomasello G; Toppo L; Ratti M; Passalacqua R
    Future Oncol; 2014; 10(9):1549-57. PubMed ID: 25145426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The safety and efficacy of ramucirumab in combination with paclitaxel for the treatment of advanced gastric or gastro-esophageal junction adenocarcinoma.
    Garrido M
    Expert Rev Anticancer Ther; 2016 Oct; 16(10):1005-10. PubMed ID: 27582051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy.
    Garcia JA; Hudes GR; Choueiri TK; Stadler WM; Wood LS; Gurtler J; Bhatia S; Joshi A; Hozak RR; Xu Y; Schwartz JD; Thompson JA
    Cancer; 2014 Jun; 120(11):1647-55. PubMed ID: 24577874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.
    Vahdat LT; Layman R; Yardley DA; Gradishar W; Salkeni MA; Joy AA; Garcia AA; Ward P; Khatcheressian J; Sparano J; Rodriguez G; Tang S; Gao L; Dalal RP; Kauh J; Miller K
    Oncologist; 2017 Mar; 22(3):245-254. PubMed ID: 28220020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ramucirumab: targeting angiogenesis in the treatment of gastric cancer.
    Smyth EC; Tarazona N; Chau I
    Immunotherapy; 2014; 6(11):1177-86. PubMed ID: 25496333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.